The lab of Jeffrey Ishizuka, MD, DPhil, develops strategies to define and target the sources of inflammation within the tumor microenvironment to improve cancer immunotherapy. They develop new tools for detecting and re-writing tumor and immune inflammatory states, identify the rules and regulatory processes of tumor innate immune sensing, and advance new therapies toward clinical development.
In this work, they use a wide variety of in vitro, in vivo, and in silico techniques, applying basic and systems immunology, functional genomics, perturbational multiomics, large language models, and in vivo models of immunotherapy efficacy.
"We seek to identify the major levers that determine tumor immune set points," says Ishizuka, “and to use these levers to advance new therapies for patients."